PART I Company Overview We are a commercial stage biotechnology company focused on the research, development, and commercialization of innovative solutions for mens health and oncology. Through our acquisition of Proteomedix, which closed on December 15, 2023, we own Proclarix, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union under the In Vitro Diagnostic Regulation (IVDR), which we anticipate will be marketed in the ...
Q2 FY2026 — expected 2026-09-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-13 | 2025-12-31 | 0001213900-26-027725 | EDGAR | 120K words |
| 2025-06-02 | 2024-12-31 | 0001213900-25-049687 | EDGAR | — |
| 2024-04-11 | 2023-12-31 | 0001213900-24-032225 | EDGAR | — |
| 2023-03-09 | 2022-12-31 | 0001213900-23-018635 | EDGAR | — |
| 2022-03-31 | 2021-12-31 | 0001213900-22-016672 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001213900-25-110142 | EDGAR | 44K words |
| 2025-08-14 | 2025-06-30 | 0001213900-25-076032 | EDGAR | — |
| 2025-06-12 | 2025-03-31 | 0001213900-25-053914 | EDGAR | — |
| 2024-12-10 | 2024-09-30 | 0001213900-24-107088 | EDGAR | — |
| 2024-08-29 | 2024-06-30 | 0001213900-24-073545 | EDGAR | — |
| 2024-05-20 | 2024-03-31 | 0001213900-24-045172 | EDGAR | — |
| 2023-11-17 | 2023-09-30 | 0001213900-23-088387 | EDGAR | — |
| 2023-10-20 | 2023-06-30 | 0001013762-23-005521 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0001213900-23-039141 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001213900-22-072376 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001213900-22-048105 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001213900-22-026516 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-27 | 0001213900-26-034902 | EDGAR | 1K words |
| 2026-03-24 | 0001213900-26-033643 | EDGAR | — |
| 2026-02-12 | 0001213900-26-015212 | EDGAR | — |
| 2026-02-09 | 0001213900-26-013724 | EDGAR | — |
| 2025-12-10 | 0001213900-25-120144 | EDGAR | — |
| 2025-12-10 | 0001213900-25-119898 | EDGAR | — |
| 2025-10-29 | 0001213900-25-103351 | EDGAR | — |
| 2025-10-03 | 0001213900-25-095847 | EDGAR | — |
| 2025-09-26 | 0001213900-25-091966 | EDGAR | — |
| 2025-09-22 | 0001213900-25-089845 | EDGAR | — |
170 total filings indexed. 143 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001782107 |
| Ticker | ONCO |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.onconetix.com |
| Listed | 2022-02-18 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report